| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PD-0332991 | GDSC1000 | pan-cancer | AAC | -0.1 | 0.002 |
| mRNA | SB-743921 | CTRPv2 | pan-cancer | AAC | -0.097 | 0.002 |
| mRNA | foretinib | GDSC1000 | pan-cancer | AAC | -0.095 | 0.003 |
| mRNA | LY-2157299 | CTRPv2 | pan-cancer | AAC | 0.23 | 0.003 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | -0.09 | 0.003 |
| mRNA | LE-135 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.004 |
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.004 |
| mRNA | BIBW2992 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.004 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.085 | 0.005 |
| mRNA | carboplatin:etoposide (40:17 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.081 | 0.005 |